Blog

Supporting the Development of Regenerative Medicines

Supporting the Development of Regenerative Medicines

Blog

Regenerative medicine is a branch of translational research which focuses on methods to regrow, repair or replace human cells, tissues or organs. We recently spoke with Michael May, President & CEO of CCRM, an organization supporting the development of regenerative medicines and associated technologies to learn more about their latest projects and collaborations.

Read More

Targeting Cancer’s Metabolic Vulnerability with IACS-10759, a Small Molecule Drug

Targeting Cancer’s Metabolic Vulnerability

Blog

Cancer cells are able to evolve to depend on two metabolic processes, glycolysis and oxidative phosphorylation. We spoke to Phil Jones from The University of Texas MD Anderson Cancer Center, to learn about the discovery and development of IACS-10759, identified as as a viable oxidative phosphorylation inhibitor.

Read More

Antibody Engineering: Driving Therapeutic Discovery and Diagnostics Forward

Antibody Engineering: Driving Therapeutic Discovery and Diagnostics Forward

Blog

We recently spoke to GenScript’s VP of Marketing, Eric Wang, to learn more about the company’s mission to “make people and nature healthier through biotechnology”. Eric discusses the key phases of antibody therapeutic discovery and development, GenScript’s role in advancing drug discovery research, and tells us about the company’s recently launched custom rabbit monoclonal antibody service.

Read More

The STING Pathway and Cancer

The STING Pathway and Cancer

Blog

STING (stimulator of interferon genes) is a key mediator of innate immunity and the STING pathway has been shown to be involved in the induction of an anti-tumor immune response. We recently spoke to Andrea van Elsas, PhD, Chief Scientific Officer at Aduro Biotech to learn more about the company’s expertise in STING Pathway Activator technology.

Read More

Therapeutic Approaches to Combat Age-Related Diseases

Therapeutic Approaches to Combat Age-Related Diseases

Blog

We recently spoke to Stanislas Veillet, Chairman and CEO of Biophytis to learn more about the company’s efforts to develop first-in-class drugs to treat degenerative illnesses associated with aging.

Read More

Genomic Profiling in Cancer: Matching Patients to Precision Trials, Guiding Patients to the Right Treatment

Genomic Profiling in Cancer: Matching Patients to Precision Trials, Guiding Patients to the Right Treatment

Blog

We recently spoke to Gaurav Singal, Vice President of Data Strategy and Product Development at Foundation Medicine, to learn more about how their SmartTrialsTM technology platform has enabled patients to be rapidly matched to precision trials, based on their unique tumor biomarkers.

Read More

Accelerating the Development of Organs-on-Chips

Accelerating the Development of Organs-on-Chips

Blog

Emulate, Inc. and AstraZeneca recently announced they have formed a collaborative partnership which will see Emulate's Organs-on-Chips technology embedded in AstraZeneca's Innovative Medicines and Early Development Biotech Unit.

Read More

Novel Neuromuscular Junction Model Benefits Drug Discovery

Novel Neuromuscular Junction Model Benefits Drug Discovery

Blog

The first functional stem-cell derived neuromuscular junction model has recently been licensed, which could help the quest to develop new drugs to treat associated neurodegenerative diseases. We caught up with James Hickman, CSO, Hesperos, to learn more about the model, and some of the benefits it brings.

Read More

Bringing Behavioral Assays to the Bench

Bringing Behavioral Assays to the Bench

Blog

How do you reliably quantify behavior? Zantiks CEO Dr. Bill Budenberg Explains

Read More

Flow Technology Innovations Driving Drug Discovery Forward

Flow Technology Innovations Driving Drug Discovery Forward

Blog

Flow chemistry is playing an increasingly prominent role in drug discovery, enabling those in the field to streamline chemistry discovery and development efforts. Finding ways to reduce the time it takes to generate validated small-molecule compounds would be highly advantageous – which is exactly why scientists at Abbvie developed SWIFT.

Read More

 
 

We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy